Social Behavior
Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics
Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors
Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion
Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.
Revolutionizing Gene Editing: Regeneron and Mammoth Biosciences’ $100M Partnership
Regeneron, Mammoth Biosciences, CRISPR, gene editing, delivery system, therapeutics, collaboration, biotechnology, healthcare innovation.
FTC’s Proposed Noncompete Ban: A Game Changer for Biopharma Job Mobility
FTC, Noncompete Ban, Biopharma Jobs, Job Mobility, Employee Rights, Competition Law
BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry
BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.
Sanofi’s BTK Inhibitor Succeeds in Phase 3 LUNA Trial, Accelerating Regulatory Approval Race
Sanofi, BTK inhibitor, LUNA trial, phase 3, regulatory approval, clinical development, blood cancer, competition
FDA Rejects Abeona’s PZ-CEL Topical Gene Therapy, Delaying Further Progress
Abeona, PZ-CEL, topical gene therapy, FDA, rejection, delay, clinical trials, EB-101, Epidermolysis Bullosa
Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success
Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.
Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases
Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)
CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns
CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.